Novartis Lp(a) drug fails closely watched ph. 3 trial

Reports

2

Domains carrying it

2

First reported

5 September 2026

Latest report

5 September 2026

◆ Sectors

◆ Timeline

1. 5 September 2026Novartis Lp(a) drug fails closely watched ph. 3 trialfiercebiotech.com
2. 5 September 2026Novartis, Ionis drug failure spurs questions about an emerging class of heart medicinesbiopharmadive.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events2 reports · 2 domains · 2 September 2026
• FDA approves Ionis' antisense drug as first targeted therapy for Alexander disease12 reports · 12 domains · 5 September 2026
• FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...18 reports · 17 domains · 1 September 2026
• Amgen submits new data to challenge FDA's proposal to withdraw Tavneos2 reports · 2 domains · 25 July 2026
• FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder14 reports · 12 domains · 1 September 2026
• IPS HEART's iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone2 reports · 2 domains · 17 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• Novartis, Ionis drug failure spurs questions about an emerging class of heart medicinesbiopharmadive.com · 5 September 2026
• Novartis Lp(a) drug fails closely watched ph. 3 trialfiercebiotech.com · 5 September 2026